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DOI 10.1016/j.ccr.2010.06.015SUMMARYMdm2 is the major negative regulator of the p53 pathway. Here, we report that Mdm2 is rapidly degraded
after DNA damage and that phosphorylation of Mdm2 by casein kinase I (CKI) at multiple sites triggers
its interaction with, and subsequent ubiquitination and destruction, by SCFb-TRCP. Inactivation of either
b-TRCP or CKI results in accumulation of Mdm2 and decreased p53 activity, and resistance to apoptosis
induced by DNA damaging agents. Moreover, SCFb-TRCP-dependent Mdm2 turnover also contributes to
the control of repeated p53 pulses in response to persistent DNA damage. Our results provide insight into
the signaling pathways controlling Mdm2 destruction and further suggest that compromised regulation of
Mdm2 results in attenuated p53 activity, thereby facilitating tumor progression.INTRODUCTION
Tumors often arise through gain of function of certain oncogenes
concomitantly with loss of key tumor suppressors. The p53
protein is considered an important tumor suppressor because
its function is compromised in >50% of human tumors (Hollstein
et al., 1991). The ability of p53 to suppress tumor development is
primarily attributed to its activity as a transcription factor that can
activate a wide variety of downstream target genes that are
responsible for p53-dependent cell-cycle arrest or apoptosis
on a variety of cellular stresses (Harms et al., 2004; Levine,
1997), such as p21 (Bunz et al., 1998; el-Deiry et al., 1993),
Gadd45, 14-3-3 (Chan et al., 1999; Wang et al., 1999), and BaxSignificance
TheMdm2/p53 pathway is compromised in >50%of human ca
by DNA damage-induced turnover of the p53 ubiquitin ligas
unclear. We demonstrated that multisite-phosphorylation by
Mdm2 destruction via SCFb-TRCP. Furthermore, theMdm2C464A
ciently degraded by SCFb-TRCP. These findings reveal a pathwa
ubiquitin ligase activity, and thereby controls p53 activity in re
b-TRCP or CKI function may contribute to the elevated Mdm2(Zhang et al., 2000). Because of its crucial role in response to
DNA damage, p53 is critical for maintaining the integrity of the
genome (Daujat et al., 2001; Harper and Elledge, 2007; Levine
et al., 2004).
Due to the important role of p53 in regulating cell proliferation
and survival, its activity has to be tightly regulated (Toledo and
Wahl, 2006). In normal unstressed cells, p53 activity must be
kept low because inappropriate activation of p53 promotes
premature senescence or apoptosis (Blaydes and Wynford-
Thomas, 1998; Mendrysa et al., 2003). On the other hand, p53
destructionmust be quickly disabled to allow for the rapid estab-
lishment of the p53 stress response (Toledo and Wahl, 2006).
Central to this regulatory mechanism is the Mdm2 protein,ncers. The dynamics of the p53/Mdm2 pathway is influenced
e Mdm2 but the underlying molecular mechanisms remain
CKI triggers both cell-cycle- and DNA damage-dependent
mutant lacking intrinsic ubiquitin ligase activity could be effi-
y that controls the stability ofMdm2 independently of its own
sponse to genotoxic stress. It further implies that defects in
expression frequently found in tumors.
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Regulation of Mdm2 Turnover by CKI/SCFb-TRCPa major negative regulator of p53, which promotes p53 ubiquiti-
nation and subsequent destruction in unstressed cells (Haupt
et al., 1997; Midgley and Lane, 1997). The N-terminus of the
Mdm2 protein interacts with p53 and its C-terminal ring-finger
domain, which possesses the ubiquitin E3 ligase activity, ubiqui-
tinates p53 (Kussie et al., 1996). The importance of Mdm2 in p53
regulation is further illustrated by the fact that the embryonic
lethal phenotype in Mdm2 knockout mice can be partially
rescued by further inactivation of the p53 protein (Montes de
Oca Luna et al., 1995).
Previous studies showed that binding of Mdm2 to p53 is
subject to many layers of regulation. Among them, the DNA
damage-induced ATM/ATR/CHK kinase cascade plays a pivotal
role. In response to stress such asDNAdamage, activation of the
ATM/ATR/CHK kinase pathway results in p53 phosphorylation,
which disrupts the interaction between Mdm2 and p53, allowing
p53 to escape Mdm2-mediated proteolysis and become stabi-
lized (Chehab et al., 2000; Harper and Elledge, 2007; Hirao
et al., 2000). It was reported that in response to DNA damage
signals, the Mdm2 protein was quickly degraded (Stommel
and Wahl, 2004), allowing p53 to accumulate and become fully
activated. However, the molecular mechanisms still remain
unclear. Although it is proposed that Mdm2 undergoes auto-
ubiquitination when cells are challenged with DNA damage
agents (Stommel and Wahl, 2004; Stommel and Wahl, 2005),
a recent study using transgenic mice provided definitive
evidence that the E3 ligase activity of Mdm2 is not required for
the proper destruction of Mdm2 (Itahana et al., 2007). This
suggests that the destruction of Mdm2 is controlled by an as
yet unknown pathway. The goal of this study was to delineate
the molecular mechanisms governing Mdm2 ubiquitination and
destruction.
RESULTS
Mdm2 Stability Is Controlled by b-TRCP
In agreement with previous reports (Itahana et al., 2007;
Stommel and Wahl, 2004), we found that Mdm2 became
unstable after DNA damage treatment in various types of cells
(Figure 1A and data not shown). Furthermore, we found that
Mdm2 protein abundance fluctuated during the cell cycle
(Figure 1B). Consistent with a more recent study showing that
the E3-ligase activity of Mdm2 is not required for Mdm2 destruc-
tion (Itahana et al., 2007), we found that the degradation of the
ring-finger mutant Mdm2C464A, which is defective in its E3 ubiq-
uitin ligase activity, was still accelerated by a variety of DNA-
damaging agents (data not shown). This data suggested that
an unknown pathway controls Mdm2 destruction in response
to genotoxic stress.
Multisubunit Cullin-Ring complexes comprise the largest
known class of E3 ubiquitin ligases (Petroski and Deshaies,
2005). We first examined whether a specific Cullin-Ring complex
is involved in controlling Mdm2 destruction. We found that
Mdm2 specifically interacts with Cullin 1, but not other members
of the Cullin family we examined (Figure 1C). We also detected
the interaction between endogenous Mdm2 and endogenous
Cullin 1 (Figure 1D). Depletion of endogenous Cullin 1 led to an
increase in Mdm2 abundance (see Figure S1A available online),
indicating that the Cullin 1 pathway might play a role in the regu-148 Cancer Cell 18, 147–159, August 17, 2010 ª2010 Elsevier Inc.lation of Mdm2 stability. Consistent with that Mdm2C464A can still
be degraded, we found that Mdm2C464A binds to Cullin 1 as effi-
ciently as wild-type Mdm2 (Figure S1B). These data together
suggest that the Cullin 1 complex might be the E3 ligase respon-
sible for Mdm2 stability independent of its auto-ubiquitination.
Next, we sought to explore which F-box protein complexed
with Cullin 1 is responsible for Mdm2 destruction. Because
Mdm2 expression fluctuates during the cell cycle (Figure 1B),
we started our investigation by using a panel of siRNAs targeting
different F-box proteins (as well as Cdh1 as a negative control)
that have been demonstrated to participate in cell-cycle
regulation. We found that depletion of b-TRCP, but not other
F-box proteins, led to a significant accumulation of Mdm2 (Fig-
ure 1E). We further found that unlike other reported b-TRCP
substrates, such as Cdc25A (Moshe et al., 2004), inactivation
of either b-TRCP1 or b-TRCP2 is sufficient to upregulate
Mdm2 (Figure 1F; Figure S1C). Additionally, ectopic expression
of b-TRCP1 engineered to resist shTRCP1 or shTRCP1+2 treat-
ment suppressed Mdm2 upregulation (Figure 1G; Figure S1D),
indicating that depletion of endogenous b-TRCP might be caus-
ative for Mdm2 upregulation. Because depletion of b-TRCP did
not increase Mdm2 mRNA level (Figure 1H), the observed
increase in Mdm2 abundance is mainly through posttranscrip-
tional mechanisms. In support of this idea, using cycloheximide,
we demonstrated that the half-life of the endogenous Mdm2
protein was extended after depletion of the b-TRCP1 protein
(Figures 1I and 1J). Furthermore, b-TRCP-mediated Mdm2
destruction occurred primarily in the late G1-S phase, as indi-
cated by the marked increase in Mdm2 abundance after deple-
tion of b-TRCP in this specific cell-cycle window (Figure S1E).
Mdm2 Interacts with b-TRCP1 in a Phosphorylation-
Dependent Manner
Consistent with a role for b-TRCP in regulating Mdm2 stability,
under ectopic overexpression conditions, Mdm2 interacts
with both b-TRCP1 and b-TRCP2 (Figure 2A). Furthermore, we
detected the interaction between endogenous Mdm2 and
endogenous b-TRCP1 (Figure 2B). The interaction between
Mdm2 and b-TRCP1 is largely reduced if the C-terminal WD40
repeats motif of b-TRCP1, which has been shown to mediate
the interaction with most of its substrates (Wu et al., 2003), is
mutated (Figure 2C). We also found that Mdm2C464A interacts
with b-TRCP1 as well (Figure S2) and that DNA damage treat-
ment enhanced the interaction between endogenous Mdm2
and endogenous b-TRCP1 (Figure 2D). In keeping with previous
reports (Frescas and Pagano, 2008; Petroski and Deshaies,
2005), we found that phosphatase treatment greatly reduced
the interaction between Mdm2 and b-TRCP1 (Figure 2E), sup-
porting the idea that Mdm2 interacts with b-TRCP1 in a phos-
phorylation-dependent manner.
Casein Kinase I Controls Mdm2 Stability
It has been suggested that most b-TRCP1 downstream targets
need to be properly modified by a combination of kinases within
their degron sequences before their recognition and destruction
by the SCFb-TRCP complex (Cardozo and Pagano, 2004; Jin et al.,
2003). We therefore sought to identify the kinase that phosphor-
ylatesMdm2 and triggers its interactionwith b-TRCP1. Examina-
tion of the Mdm2 protein sequence did not reveal a canonical
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Figure 1. Mdm2 Stability Is Controlled by
b-TRCP
(A) U2OS cells were treated with 25 mM etoposide
for 1.5 hr before 20 mg/ml cycloheximide was
added. At the indicated time points, whole-cell
lysates were prepared and immunoblots were
probed with the indicated antibodies.
(B) Immunoblot analysis of HeLa cells synchro-
nized by growth in nocodazole and then released
for the indicated periods of time.
(C) Immunoblot analysis of whole-cell lysates
(WCL) and immunoprecipitates (IP) derived from
293T cells transfected with HA-Mdm2 and various
Myc-tagged Cullin constructs. Twenty hours post-
transfection, cells were treated with 10 mMMG132
overnight before harvesting.
(D) Immunoblot analysis of HeLa cell whole-cell
lysates (WCL) and anti-Mdm2 immunoprecipitates
(IP). Flag- and HA-agarose beads were used as
negative controls for the immunoprecipitation
procedure. Cells were treated with 10 mM MG132
overnight before harvesting.
(E) Immunoblot analysis of HeLa cells transfected
with the indicated siRNA oligonucleotides. The
control lane is scrambled E2F-1 siRNA; Luciferase,
siRNA against firefly luciferase; b-TRCP1+2,
siRNA oligo that can deplete both b-TRCP1 and
b-TRCP2 isoforms. siRNA, short interfering RNA.
(F) Immunoblot analysis of HeLa cells transfected
with the indicated shRNA constructs.
(G) Immunoblot analysis of 293T cells transfected
with the indicated shRNA constructs together
with HA-Mdm2 and jellyfish GFP (eGFP, as
transfection controls). Where indicated, Flag-b-
TRCP1*, which is engineered to resist the shb-
TRCP1 effect, was included in the transfection.
(H) Real-time RT-PCR analysis to examine the rela-
tive Mdm2 mRNA expression levels in U2OS cells
transfected with the indicated siRNA oligonucleo-
tides. Three independent sets of experiments
were performed to generate the error bar. The error
bars represent ± SD.
(I) HeLa cells were transfected with the indicated
shRNA constructs. Twenty hours posttransfection,
cells were split into 60 mm dishes and, after
another 20 hr, treated with 20 mg/ml cycloheximide. At the indicated time points, whole-cell lysates were prepared, and immunoblots were probed with the indi-
cated antibodies.
(J) Quantification of the band intensities in (I). Mdm2 band intensity was normalized to tubulin, then normalized to the t = 0 controls.
See also Figure S1.
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Regulation of Mdm2 Turnover by CKI/SCFb-TRCPdegron sequence (DSGxxS) that could be recognized by the
SCFb-TRCP E3 ligase complex (Cardozo and Pagano, 2004).
Thus, we used the PESTfinder program to identify two strong
PEST sequences, which are typically associated with protein
instability where putative degron sequences might reside, within
the Mdm2 protein sequence (Figure S3A). The Scansite program
predicted that most of the putative phosphorylation sites within
these two PEST sequences are either CKI or casein kinase II
(CKII) sites. Hence, we began to investigate the potential role
of CKI or CKII in Mdm2 stability control.
In support of the notion that CKI is the upstream kinase trig-
gering b-TRCP1-mediated Mdm2 destruction, we found that
GST-Mdm2 cannot be recognized by b-TRCP1 in vitro unless it
is phosphorylated by purified CKI, but not CKII (Figure 3A). Using
coimmunoprecipitation and GST pull-down assays we foundthat Mdm2 interacted with CKIa1, CKIa2, CKId, and CKI3
(Figures S3B and S3C) (Winter et al., 2004). We also detected
the interaction between endogenous Mdm2 and endogenous
CKId (Figure 3B), further supporting the physiological role of
CKId in regulating Mdm2 stability. Consistent with this finding,
overexpression of CKId and CKI3, and to less extent CKIa1
andCKIa2, reducedMdm2protein level (Figure 3C). On the other
hand, expression of CKIg1 and CKIg2, or a kinase-dead mutant
of CKId (K38R) (Peters et al., 1999) failed to promote Mdm2
destruction (Figures S3E–S3G).
Furthermore, inactivation of CKI by the small-molecule
inhibitor D4476 (Rena et al., 2004), resulted in accumulation of
endogenous Mdm2 (Figure 3D) as well as a moderate increase
in resistance to etoposide-induced Mdm2 destruction (Fig-
ure 3E). Consistent with a role for CKI in Mdm2 stability control,Cancer Cell 18, 147–159, August 17, 2010 ª2010 Elsevier Inc. 149
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Figure 2. Mdm2 Interacts with b-TRCP in
a Phosphorylation-Dependent Manner
(A) Immunoblot analysis of whole-cell lysates
(WCL) and immunoprecipitates (IP) derived from
293T cells transfected with HA-Mdm2 and Myc-
tagged b-TRCP constructs. Twenty hours post-
transfection, cells were treated with 10 mMMG132
overnight before harvesting.
(B) Immunoblot analysis of HeLa cell whole-cell
lysates (WCL) and anti-Mdm2 immunoprecipitates
(IP). HA-agarose beads were used as a negative
control for the IP. Cells were treated with 10 mM
MG132 overnight before harvesting.
(C) Immunoblot analysis of whole-cell lysates
(WCL) and immunoprecipitates (IP) derived from
293T cells transfected with HA-Mdm2 and the
indicatedMyc-tagged b-TRCP constructs. Twenty
hours posttransfection, cells were treated with
10 mM MG132 overnight before harvesting.
(D) Immunoblot analysis of HeLa cell whole-cell
lysates (WCL) and anti-Mdm2 immunoprecipitates
(IP). HA-agarose beads were used as a negative
control for the IP. Cells were treated with 10 mM
MG132 overnight before harvesting. Where indi-
cated, cells were treated with 25 mM etoposide
(or DMSO as a negative control) for 30 min before
harvesting.
(E) Autoradiograms showing recovery of
35S-labeled b-TRCP1 protein bound to Mdm2
protein immunoprecipitated from HeLa cells
transfected with the indicated HA-Mdm2 con-
structs. Where indicated, the whole-cell lysates
were treated with l-phosphatase before immuno-
precipitation. IN, input (10% or 5% as indicated).
See also Figure S2.
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Regulation of Mdm2 Turnover by CKI/SCFb-TRCPinhibition of CKId activity by inhibitors (Figure S3H) or shRNA
treatment (Figure 3F) significantly reduced the interaction
between Mdm2 and b-TRCP1. Furthermore, depletion of CKI
(mainly the CKId and CKI3 isoforms) led to elevated Mdm2 abun-
dance (Figure 3G and Figures S3I and S3J), and extendedMdm2
half-life (Figures S3K and S3L), indicating that CKId and CKI3
might be the major isoforms regulating Mdm2 stability. DNA
damage induced the interaction between endogenous Mdm2
and CKId (Figure 3H), providing a direct link between CKId and
Mdm2 destruction after DNA damage response. In agreement
with a previous report (Alsheich-Bartok et al., 2008), we found
that CKId resides in the cytoplasm in nonstressed cells, but in
response to DNA damage, a significant fraction of endogenous
CKId translocated into the nucleus (Figures S3M and S3N).
CKId Phosphorylates Mdm2 at Multiple Sites to Trigger
Mdm2/b-TRCP1 Interaction
The absence of a canonical degron sequence in the Mdm2
protein sequence suggests that Mdm2 might contain multiple
suboptimal degron sequences instead of one optimized degron.
In support of this notion, using mass spectrometry analysis, we
found that CKId phosphorylates GST-Mdm2 at multiple sites
in vitro (Figures S4A and S4B). In addition to the CKI sites we
identified, Mdm2 has also been reported to be phosphorylated
by CKI at multiple sites in vivo (Figure S4D) (Winter et al.,
2004). To further evaluate the physiological relevance of Mdm2150 Cancer Cell 18, 147–159, August 17, 2010 ª2010 Elsevier Inc.phosphorylation for its stability, we blocked the proteasome
pathway with MG132 then analyzed the Mdm2 phosphorylation
status with mass spectrometry. We found that proteasome
inhibition resulted in increased phosphorylated Mdm2 species
(Figure S4C), many of which overlapped with those identified
in the in vitro CKId kinase assay (Figure S4B). Importantly,
these phosphorylation sites resemble the DSGxxS degron site
(Figure S4E).
Interestingly, the majority of the putative CKI sites reside in the
two identified PEST sequences (Figure S3A and Figures S4A–
S4C). We named the PEST sequence containing the acidic
domain the p2 region, and the PEST sequence containing the
SQ cluster domain the p3 region (Figure S3A and Figure S4A).
We noticed that the Ser121 site (DSGTSVS) identified by mass
spectrometry residing outside the two PEST sequences, how-
ever, most resembles the canonical degron sequence (Fig-
ure S4F). We named this region p1. To better understand the
contribution of this putative degron to Mdm2 stability control,
we developed phosphorylation-specific antibodies that recog-
nize the phosphorylated state of Ser118 and Ser118/Ser121.
Using these two antibodies, we demonstrated that these two
sites were indeed phosphorylated in vivo (Figures S4G–S4I).
Furthermore, inhibition of CKId by either CKI inhibitors or shRNA
treatment led to a reduction in phosphorylation on both Ser118
and Ser121 of Mdm2 (Figures S4J and S4K). On the other
hand, depletion of b-TRCP1 resulted in a dramatic increase
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Figure 3. CKI Is Involved in Regulating Mdm2 Stability
(A) Autoradiograms showing recovery of 35S-labeled b-TRCP1 protein bound to GST-Mdm2 fusion proteins (GST protein as a negative control) incubated with the
indicated kinase before the pull-down assays. IN, input (10% or 2% as indicated). 35S labeling was carried out by in vitro translation reaction with retic lysate.
(B) Immunoblot analysis of whole-cell lysates (WCL) and anti-Mdm2 immunoprecipitates (IP) derived from the indicated HeLa stable cell lines generated by infec-
tion with shGFP or shCKId lentiviral construct and subsequent selection with 1 mg/ml puromycin to eliminate the noninfected cells. HA-agarose beads were used
as a negative control for the immunoprecipitation procedure. Cells were treated with 10 mM MG132 overnight before harvesting.
(C) Immunoblot analysis of whole-cell lysates (WCL) derived from 293T cells transfected with various Myc-tagged CKI constructs to detect the changes in endog-
enous Mdm2 expression.
(D) Immunoblot analysis of HeLa cells treated with the CKI inhibitor D4476 at the indicated concentrations for 12 hr.
(E) HeLa cells were transiently transfected with the HA-Mdm2 plasmid together with Flag- b-TRCP1. Twenty-four hours posttransfection, cells were treated with
the indicated CKI inhibitor for 4 hr and then incubatedwith 25 mMetoposide for an additional 1.5 hr. The whole-cell lysates were recovered and immunoblots were
performed with the indicated antibodies.
(F) Immunoblot analysis of whole-cell lysates (WCL) and immunoprecipitates (IP) derived from 293T cells transfected with HA-Mdm2 and Myc-tagged b-TRCP
constructs. Where indicated, the shGFP or shCKId construct was included in the transfection. Twenty hours posttransfection, cells were treated with 10 mM
MG132 overnight before harvesting.
(G) Immunoblot analysis of HeLa cells transfected with the indicated shRNA constructs.
(H) Immunoblot analysis of HeLa cell whole-cell lysates (WCL) and anti-Mdm2 immunoprecipitates (IP). HA-agarose beads were used as a negative control for the
IP. Cells were treated with 10 mMMG132 overnight before harvesting. Where indicated, cells were treated with 25 mM etoposide (or DMSO as control) for 30 min
before harvesting.
See also Figure S3.
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Regulation of Mdm2 Turnover by CKI/SCFb-TRCPof phosphorylation on both Ser118 and Ser121 of Mdm2
(Figure S4K).
Although phosphorylation of both Ser118 and Ser121 within
the p1 region is sufficient for a Mdm2 peptide to interact with
b-TRCP1 (Figures S4L–S4N), mutation or deletion of these two
putative CKI phosphorylation sites did not abolish the ability of
Mdm2 to interact with b-TRCP in vivo (Figures S4O and S4P),
indicating that Mdm2 might contain additional b-TRCP recogni-tion motifs. To further understand their contributions to Mdm2
destruction, we created a panel of Mdm2 mutants where the
DSG site (p1), acidic domain (p2), and the SQ cluster (p3) regions
were deleted individually or in combination (Figure S4Q).We also
generated mutants wherein the potential critical Ser/Thr sites
for individual suboptimal degrons, including some experimen-
tally identified putative CKI phosphorylation sites, were point-
mutated (Figure 4A; Figures S4E and S4R).Cancer Cell 18, 147–159, August 17, 2010 ª2010 Elsevier Inc. 151
A B
C
Figure 4. CKId Phosphorylates Mdm2 at Multiple Sites to Trigger Mdm2 Interaction with b-TRCP1
(A) Illustration of the various Mdm2 mutants generated for this study.
(B) Sequential inactivation of the potentially critical Ser/Thr sites for individual suboptimal degrons including the identified major CKId phosphorylation sites
leads to progressive reduction of in vitro Mdm2 phosphorylation signals. Purified CKId protein (New England BioLabs) was incubated with 5 mg of the indicated
GST-Mdm2 proteins in the presence of g-32P-ATP. The kinase reaction products were resolved by SDS-PAGE, and phosphorylation was detected by autora-
diography.
(C) Consequently, the recovered in vitro b-TRCP1/Mdm2 interaction is reduced in a step-wise manner after sequential inactivation of the identified Ser/Thr phos-
phorylation sites in Mdm2, indicating that phosphorylation of Mdm2 at multiple sites by CKId triggers its interaction with b-TRCP1 in vitro. Autoradiograms
showing recovery of 35S-labeled b-TRCP1 protein bound to the indicated GST-Mdm2 fusion proteins (GST protein as a negative control) incubated with CKId
before the pull-down assays. IN, input (5% as indicated).
See also Figure S4.
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Regulation of Mdm2 Turnover by CKI/SCFb-TRCPUsing in vitro kinase assays, we found that deletion of the p2
region greatly reduced the ability of CKId to phosphorylate
Mdm2 (Figure S4S). We also found that deletion of either the
p1 or p3 regions further reduced the phosphorylation by CKId,
indicating that CKId also phosphorylates Mdm2 in the DSG
and SQ cluster regions (Figure S4S). More interestingly, we
observed a progressive reduction of the CKId-mediated phos-
phorylation after mutating the major phosphorylation sites
identified by mass spectrometry analysis in a step-wise fashion
(Figure 4B). These Mdm2 mutants interact with CKId with similar
efficacy as the wild-type Mdm2 (Figures S4T and S4U), which
indicates that the loss of phosphorylation of these mutants is
not due to loss of their interaction with the CKId kinase. Alto-
gether, these results support a possible model that CKId
phosphorylates Mdm2 at multiple sites, which closely resembles
the way GSK3 and PKA phosphorylate the Gli3 oncoprotein (Jia
et al., 2005; Tempe et al., 2006). Importantly, we found that the
ability of various Mdm2 species to interact with b-TRCP1 corre-152 Cancer Cell 18, 147–159, August 17, 2010 ª2010 Elsevier Inc.lated very well with their CKId phosphorylation status (Figure 4C;
Figure S4V). Taken together, this data indicates that phosphory-
lation of Mdm2 by CKId at multiple sites is critical for triggering
the interaction of Mdm2 with b-TRCP.
CKId Phosphorylates Mdm2 at Multiple Sites to Trigger
Mdm2 Destruction
Next, we exploredwhether b-TRCPpromotesMdm2destruction
in a CKId phosphorylation-dependent manner. We found that
the degree of decrease in CKId-mediated phosphorylation of
the various Mdm2 mutants correlated with their resistance to
b-TRCP-induced proteolysis (Figures 5A and 5C). Inactivation
of the E3-ligase activity of Mdm2 by mutating its ring-finger
domain (C464A) did not interfere with the ability of b-TRCP and
CKId to degrade the Mdm2 protein (Figure 5B).
Degrons can serve to recruit E3 ligases when fused to arti-
ficial substrates. To test whether the identified Mdm2 degron
sequences can function outside the context of Mdm2, the p1
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Figure 5. CKId Phosphorylates Mdm2 at
Multiple Sites to Trigger Mdm2 Destruction
by b-TRCP1
(A) Immunoblot analysis of HeLa cells transfected
with the indicated HA-Mdm2 and Flag-b-TRCP1
plasmids in the presence or absence of Myc-
CKId. A plasmid encoding GFP was used as a
negative control for transfection efficiency. Where
indicated, the proteasome inhibitor MG132
(10 mM) was added.
(B) Immunoblot analysis of HeLa cells transfected
with various HA-Mdm2C464A constructs (with
wild-type Mdm2 as a positive control) and Flag-
b-TRCP1 plasmids in the presence or absence of
Myc-CKId. A plasmid encoding GFP was used as
a negative control for transfection efficiency.
(C) Immunoblot analysis of HeLa cells transfected
with the indicated HA-Mdm2 and Flag-b-TRCP1
plasmids in the presence or absence of Myc-
CKId. A plasmid encoding GFP was used as
a negative control for transfection efficiency.
(D) Illustration of the various GST-Mdm2 con-
structs used in (E) and Figure S5.
(E) Immunoblot analysis of HeLa cells transfected
with the indicated GST-Mdm2 and Flag-b-TRCP1
plasmids in the presence or absence of Myc-
CKId. A plasmid encoding GFP was used as a
negative control for transfection efficiency.
See also Figure S5.
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Regulation of Mdm2 Turnover by CKI/SCFb-TRCPor p2 region was fused with the GST protein and their response
to b-TRCP1-mediated protein degradation was examined. GST-
p1 and GST-p2 were susceptible to b-TRCP-mediated destruc-
tion (Figures 5D and 5E; Figure S5) whereas those with key CKI
phosphorylation sites mutated or deleted were not (Figure 5E;
Figure S5). These results strongly support the hypothesis that
phosphorylation of Mdm2 by CKId at the p1 and p2 regions are
both sufficient and required to trigger Mdm2 destruction.
Mdm2 Protein Abundance Is Controlled by Both
Auto- and b-TRCP-Dependent Ubiquitination Pathways
during Cell-Cycle Progression
In agreement with a previous report (Gu et al., 2003), we found
that Mdm2C464A was more stable than WT-Mdm2 during the
cell cycle (Figure 6A). However, Mdm2C464A was still unstable
in the early G1 phase. Importantly, the Dp1p2p3 mutant, whichCancer Cell 18, 147–159cannot be phosphorylated by CKId, was
more stable than WT-Mdm2 in most
cell-cycle phases and additional C464A
mutation moderately increased its abun-
dance (Figure 6A). These results suggest
that both self-ubiquitination and b-TRCP-
mediated ubiquitination play important
roles in mediating the timely destruction
of Mdm2 during cell-cycle progression.
However, Dp1p2p3/C464A was still un-
stable in certain cell-cycle phases, indi-
cating that there might be additional
unknown pathway(s) involved in Mdm2
stability control. The half-life of Mdm2
was greatly extended after inactivationof either self-ubiquitination (C464A-Mdm2) or b-TRCP-mediated
(Dp1p2p3-Mdm2) ubiquitination (Figure S6A). Furthermore,
depletion of endogenous b-TRCP via shRNA treatment resulted
in a sharp increase in the abundance of both the wild-type and
C464A mutant Mdm2 proteins (Figure 6B), indicating that both
could still be degraded by the b-TRCP pathway.
b-TRCP Promotes Mdm2 Turnover and Ubiquitination
The observed progressive increase in Mdm2 stability after
sequential mutation of multiple potential CKI sites (Figure 5C)
might be due to inefficient b-TRCP-dependent proteolysis.
In support of this idea, coexpression of CKId and b-TRCP1
resulted in a marked reduction in the half-life of wild-type (Fig-
ure 6C) and Mdm2C464A (Figure S6B), whereas it did not affect
the half-life of the Dp1-23A (Figure 6C) and Dp1p2p3 Mdm2
mutants (Figure S6B). Importantly, the Dp1-23A Mdm2 mutant, August 17, 2010 ª2010 Elsevier Inc. 153
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Figure 6. b-TRCP Controls Mdm2 Protein
Abundance during the Cell-Cycle Progres-
sion and Promotes the Ubiquitination of
the Mdm2 Protein
(A) Immunoblot analysis of HeLa cells transfected
with the indicated HA-Mdm2 plasmids, synchro-
nized by growth in nocodazole, and then released
for the indicated periods of time.
(B) Immunoblot analysis of HeLa cells transfected
with the indicated HA-Mdm2 plasmids together
with the shb-TRCP1+2 construct (or shGFP as
a negative control), synchronized by growth in
nocodazole, and then released for the indicated
periods of time.
(C) HeLa cells were transfected with the indicated
HA-Mdm2 constructs together with the Flag-b-
TRCP1 and Myc-CKId plasmids. Twenty hours
posttransfection, cells were split into 60 mm
dishes, and after another 20 hr, treated with
20 mg/ml cycloheximide. At the indicated time
points, whole-cell lysates were prepared and
immunoblots were probed with the indicated anti-
bodies.
(D) SCF/b-TRCP1 promotes Mdm2 ubiquitination
in vitro in a CKI-phosphorylation-dependent
manner. Purified CKId protein (from New England
BioLabs, or kinase buffer as a negative control)
was incubated with 5 mg of the indicated GST-
Mdm2 proteins in the presence of ATP. The kinase
reaction products were incubated with purified E1,
E2, ubiquitin, and/or SCF/b-TRCP1 as indicated in
30C for 45 min. The ubiquitination reaction prod-
ucts were resolved by SDS-PAGE and probedwith
the indicated antibodies.
See also Figure S6.
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Regulation of Mdm2 Turnover by CKI/SCFb-TRCPinteracts with p53 similarly to wild-type Mdm2 (Figure S6C) and
degrades p53 as efficiently as wild-type Mdm2 (Figure S6D).
Collectively, these results indicate that these mutations did not
alter the function of the Dp1-23A Mdm2 mutant, and that the
observed stability increase in the Dp1p2p3 Mdm2 mutant might
not be due to gross conformational changes.
Consistent with this result, coexpression of CKId and b-TRCP
promoted the ubiquitination of the Mdm2C464A protein, but
ubiquitination of the CKI-phosphorylation defective (Dp1p2p3)
Mdm2C464A mutant was greatly reduced (Figure S6E). More
importantly, purified SCF/b-TRCP E3 ligase complex could
promote the ubiquitination of GST-Mdm2C464A protein in vitro
in a CKI-phosphorylation-dependent manner, whereas its ability154 Cancer Cell 18, 147–159, August 17, 2010 ª2010 Elsevier Inc.to ubiquitinate CKI-phosphorylation-
defective Mdm2C464A mutants (Dp1p2p3
and Dp1-23A) is significantly reduced
(Figure 6D).
b-TRCP Promotes DNA Damage-
Dependent Turnover of Mdm2
Next, we asked how manipulation of the
b-TRCP-mediated Mdm2 destruction
pathway affects p53 activity and its
cellular functions in response to DNA
damage. As shown in Figure 7A andFigures S7A and S7B, inactivation of b-TRCP partially blocked
the destruction of Mdm2 in response to DNA damaging agents.
Inactivation of CKId by shRNA treatment also partially blocked
DNA damage-induced destruction of Mdm2 (Figure S7B). To
further understand the role of b-TRCP1 in regulating the
Mdm2/p53 pathway, we performed b-TRCP1 siRNA experi-
ments in the U2OS cell line. As shown in Figure 7B, inactivation
of b-TRCP led to increased Mdm2 abundance in the late
G1-S phase, and this resulted in decreased p53 protein
(Peschiaroli et al., 2006) and the p53’s downstream targets,
p21 and Bax (Figure 7B). Correspondingly, this resulted in
elevated resistance to DNA damage-induced apoptosis (Fig-
ure 7C). Using p53/ HCT116 cells or p53 siRNA-treated
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Figure 7. Depletion of b-TRCP Results in
Resistance to Apoptosis by Affecting the
Mdm2/p53 Pathway
(A) Immunoblot analysis of HeLa cells transfected
with the indicatedsiRNAoligos.Twentyhourspost-
transfection, cells were treated with the indicated
DNA damage drugs for 3 hr before harvesting.
(B) Immunoblot analysis of U2OS cells transfected
with the indicated siRNA oligos, after synchroniza-
tion with hydroxyurea and release.
(C) U2OS cells were transfected with the indicated
siRNA oligos. Twenty hours posttransfection, cells
were treated with hydroxyurea for 16 hr, and then
treated with 1.7 mM doxorubicin for 2 hr before
release to normal medium. Twelve hours later,
cells were recovered for FACS analysis for detec-
tion of the apoptotic (sub-G1) cell population.
Error bars represent ± SD.
(D) Immunoblot analysis of MCF7 cells transfected
with the indicated siRNA oligos. Twenty hours
posttransfection, cells were treated with NCS,
and whole-cell lysates were collected at the indi-
cated time points.
(E) Quantification of the band intensity in (D). p53
and Mdm2 band intensities were normalized to
tubulin, then normalized to the t = 0 controls.
Three independent sets of experiments were per-
formed to generate the error bars. Error bars
represent ± SD.
See also Figure S7.
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Regulation of Mdm2 Turnover by CKI/SCFb-TRCPU2OS cells, we demonstrated that b-TRCP-depletion-induced
resistance to apoptosis is partially through the p53 pathway
(Figures S7C–S7G). Mdm2 might be required for this phenotype
because further depletion of Mdm2 induced apoptosis in
cells whose endogenous b-TRCP has been depleted (Fig-
ure 7C and Figures S7H and S7I). However, the lack of a full
recovery in the b-TRCP/Mdm2 double siRNA treated sample
to levels of apoptosis observed in the Mdm2 single siRNA
treated sample indicate that other potential b-TRCP1 substrate
(s) (Ding et al., 2007) might also influence the ability of b-TRCP
to regulate the cellular apoptotic pathway independent of
Mdm2. Importantly, depletion of endogenous b-TRCP resulted
in elevated Mdm2 expression in p53/ HCT116 cells as
well, indicating that this process is p53-independent (Fig-
ure S7G). Furthermore, consistent with increasedMdm2 expres-
sion, depletion of endogenous b-TRCP in WT-HCT116 cells
resulted in reduced p53 and subsequent p21 expression
(Figure S7G). As a result, it led to increased BrdU incorporation
(Figure S7J) and a moderate increase in xenografted tumor
growth (Figure S7K).Cancer Cell 18, 147–159Previous studies have revealed that
p53 levels oscillate in MCF7 cells sub-
jected to DNA damage (Batchelor et al.,
2008; Hu et al., 2007). These oscillations
reflect pulsatile signaling of the ATM/
Chk2 pathway and negative feedback on
p53 including the Mdm2-p53 feedback
loop, wherein p53 induction by DNA
damage is accompanied by increased
Mdm2expression,which in turnpromotessubsequent p53 turnover. In this process, negative feedback by
Mdm2 contributes to the reduction in p53 levels after the initial
pulse, but is not sufficient to trigger continuous p53 pulses
(Batchelor et al., 2008). As expected, DNA damage resulted in
oscillations of both p53 and Mdm2 expression in MCF7 cells
(Figure 7D). Although the first p53 pulse after DNA damage was
normal, depletion of b-TRCP resulted in increased Mdm2 levels
and the second pulse of p53 was substantially reduced (Figures
7D and 7E). Furthermore, we found that inhibition of CKId by
inhibitors (Figure S7L) or shRNA treatment (Figure S7M) also
attenuated the p53 pulse in response to continuous DNA
damage. Thus, CKId/SCFb-TRCP-dependent Mdm2 turnover
contributes to the control of p53 dynamics in response to DNA
damage that has been suggested to be important for the tumor
suppressor function of p53 (Hu et al., 2007).
DISCUSSION
The data presented here provides evidence for a molecular
mechanism by which CKI-dependent phosphorylation of Mdm2, August 17, 2010 ª2010 Elsevier Inc. 155
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Figure 8. Proposed Model for the CKI/SCFb-TRCP Pathway that
Controls Cell-Cycle-Regulated and DNA Damage-Dependent
Mdm2 Turnover
DNA damage and possibly cell-cycle stimulatory signals trigger the transloca-
tion of CKI from the cytoplasm, where it resides in nonstressed conditions, into
the nucleus. This results in enhanced interaction between CKId and Mdm2,
and subsequently multisite phosphorylation of Mdm2 by CKId. Phosphoryla-
tion of these multiple suboptimal degron sequences function combinatorially
to facilitate Mdm2 recognition and destruction by the SCFb-TRCP pathway,
thereby setting up a switch for Mdm2 destruction in response to DNA damage
and during the cell cycle. Inactivation of either b-TRCP or CKI results in accu-
mulation of Mdm2 and decreased p53 activity, thus perturbing the proper
establishment of the p53 stress response and subsequently facilitates tumor
progression.
Cancer Cell
Regulation of Mdm2 Turnover by CKI/SCFb-TRCPat multiple sites triggers SCFb-TRCP-mediated Mdm2 destruction
(Figure 8). It is well recognized that most F-box proteins,
including b-TRCP, interact with their ubiquitin substrates only
after they are properly phosphorylated (Petroski and Deshaies,
2005). Therefore, the destruction of these substrates is regulated
primarily at their phosphorylation by appropriate kinases. In the
case of Mdm2, specific CKI isoforms control the timing of
Mdm2 turnover. In support of this idea, blocking CKI activity
resulted in a marked increase in the steady-state abundance of
Mdm2. It is known that CKI activity is subject to many layers of
regulation (Giamas et al., 2007; Knippschild et al., 2005; Swiatek
et al., 2004). Here we report the nuclear localization of CKId
and its interaction with Mdm2 was enhanced in response to
DNA damage. However, additional studies are required to fully
understand the molecular mechanisms by which CKId activity
is regulated in response to DNA damage and during cell-cycle
progression.
We demonstrated that the major CKI phosphorylation sites
are located in the Mdm2 acidic domain (p2), whereas other
minor CKI sites are located in the N-terminal DSG site (p1)
and the C-terminal SQ cluster (p3) region. More interestingly,
sequential inactivation of the potentially critical Ser/Thr sites for
suboptimal degrons in Mdm2 resulted in a progressive reduction
of CKI-mediated phosphorylation (Figure 4B), which correlated
well with reduced interaction ofMdm2with b-TRCP1 (Figure 4C),
and reduced destruction of Mdm2. Furthermore, individual
mutation of each phosphorylation site did not show considerable
protection against b-TRCP1/CKId-mediated destruction (data
not shown). This suggests that, in contrast to many known
b-TRCP1 substrates that contain one optimized canonical
degron sequence, such as Emi-1 or Claspin, the Mdm2 protein156 Cancer Cell 18, 147–159, August 17, 2010 ª2010 Elsevier Inc.containsmany suboptimal degron sequences that are phosphor-
ylated by CKI. Other b-TRCP1 substrates, including Cdc25A
(Kanemori et al., 2005) and Gli3 (Pan et al., 2006; Tempe et al.,
2006; Wang and Li, 2006), are also known to contain multiple
degron sequences. A similar mechanism has been described
for SCFCdc4-dependent turnover of the Sic1 Cdk inhibitor (Nash
et al., 2001). Multisite phosphorylation likely represents a more
general mechanism for creating switch-like transitions via SCF-
dependent turnover pathways (Ferrell, 2001; Harper, 2002).
Our studies suggested that the cumulative, multisite phosphory-
lation of Mdm2 by CKIdmight set up a switch for Mdm2 destruc-
tion in response to DNA damage and during the cell cycle.
It was reported previously that Mdm2 auto-ubiquitination
plays an important role in DNA-damage triggered Mdm2
destruction (Stommel and Wahl, 2004). However, in agreement
with a recent report (Itahana et al., 2007), we found that
Mdm2C464A could be efficiently degraded in response to various
types of DNA damage agents (data not shown). More impor-
tantly, coexpression of CKId and b-TRCP1 promotes destruction
of Mdm2C464A, but not Dp2- Mdm2C464A, as efficiently as the
wild-type Mdm2 (Figure 5B). These findings suggest that CKI-
mediated phosphorylation, rather than the ring-finger domain,
might be critical for Mdm2 destruction after DNA damage.
Nevertheless, Mdm2 auto-ubiquitination also plays a critical
role in regulating the steady state level of Mdm2 during the cell
cycle, as Mdm2C464A was more stable than wild-type Mdm2 in
synchronous cell-cycle release experiments (Figure 6A). Consis-
tent with gain-of-function experiments, depletion of b-TRCP1
also stabilized Mdm2C464A (Figure 6B). Taken together, these
data indicate that constitutive Mdm2 destruction during the
cell cycle is tightly regulated by both auto-ubiquitination and
b-TRCP1-mediated ubiquitination pathways.
Mdm2 is an oncoprotein that is frequently overexpressed
in tumors, which enhances cellular transformation (Momand
et al., 2000). Although amplification of the mdm2 locus has
been found in some cases, the molecular mechanism leading
to elevated Mdm2 expression in most tumors remains unclear.
Our studies suggested that disruption of the Mdm2 destruction
pathway could potentially contribute to increased Mdm2
abundance. This could be achieved by inactivation of its E3
ligase b-TRCP1 (Frescas and Pagano, 2008; Nakayama and
Nakayama, 2005), inactivation of its modifying enzyme CKI, or
by acquiring mutations that disrupt its phosphorylation by CKI.
Similarly, both c-myc gene amplification and mutations within
the degron sequence are thought to contribute to c-Myc overex-
pression in cancers (Welcker et al., 2004). In this regard, it is
interesting that alterations in b-trcp1 have been reported in
many types of cancers (Nakayama and Nakayama, 2005). Our
data suggest that a compromised Mdm2 destruction pathway
might lead to enhanced Mdm2 oncogenic activity by promoting
p53 destruction and thus facilitating tumor progression. Further
studies may reveal the extent to which the CKI/b-TRCP pathway
and its linkage to Mdm2 is disrupted in cancer.EXPERIMENTAL PROCEDURES
siRNAs
Human siRNA oligo that can deplete both b-TRCP1 and b-TRCP2 (sense,
50-AAGUGGAAUUUGUGGAACAUC-30 ) has been validated previously
Cancer Cell
Regulation of Mdm2 Turnover by CKI/SCFb-TRCP(Jin et al., 2003) and was purchased from Dharmacon. Human siRNA oligos
against Cullin-1, Fbw7, Skp2, and Cdh1 have been described previously
(Benmaamar and Pagano, 2005; Wei et al., 2004; Wei et al., 2005). Human
siRNA oligos that can deplete Mdm2 (Mdm2: sense, 50-AAGCCATTGCTTTT
GAAGTTA-30 ), or p53 (sense, 50-AAGGATGCCCAGGCTGGGAAG-30) were
purchased from Dharmacon. Luciferase GL2 siRNA oligo was purchased
from Dharmacon. As described previously, siRNA oligos were transfected
into subconfluent cells using Oligofectamine or Lipofectamine 2000 (Invitro-
gen) according to the manufacturer’s instructions (Wei et al., 2004; Wei
et al., 2005). Transient transfection of the control and b-TRCP siRNA oligos
into MCF7 cells was performed according to the manufacturer’s instructions
(Amaxa Biosystems).
Cell Culture and Cell Synchronization
Cell culture including synchronization and transfection have been described
(Wei et al., 2004). To perform U2OS cell synchronization, 2 mM hydroxyurea
was added into U2OS cells cultured at subconfluence (around 20%–25%) to
arrest cells at the late G1 phase. After 18 hr, cells were washed three times
with warm PBS and then freshly made DMEM medium containing 10% FBS
was added. Lentiviral shRNA virus packaging and subsequent infection was
performed as described previously (Boehm et al., 2005).
Xenografted Tumor Growth Assays
Six-week-old female nude mice (Taconic) were used for xenograft studies.
Approximately 1.5 3 106 viable tumor cells were resuspended in 50 ml
PBS solution and injected subcutaneously into the mice (n = 6 mice for
each group) and the bioluminescent imaging and normalization were per-
formed as described previously (Zhang et al., 2009). Briefly, for biolumines-
cent detection and quantification of the xenografted tumor cells, mice were
given a single intraperitoneal injection of a mixture of luciferin (50 mg/kg),
ketamine (150 mg/kg), and xylazine (12 mg/kg) in sterile water. Five
minutes later, mice were placed in a light-tight chamber equipped with a
charge-coupled device IVIS imaging camera (Xenogen). Photons were
collected for a period of 1–60 s, and images were obtained by using LIVING
IMAGE 2.60.1 software (Xenogen) and quantified using IGOR Pro 4.09A
image analysis software (WaveMatrics). The total photons from the b-TRCP1
shRNA tumor region of interest (ROI) were divided by the total photons
from GFP shRNA tumor ROI and, for each mouse, normalized based on
the natural log of the ratio of the initial bioluminescent imaging (day 0) for
that mouse. Results were presented as mean ± standard error of the mean
(SEM). All mice experiments were approved by the Harvard University and
Dana-Farber Cancer Institute Institutional Animal Care and Use Committee,
and the experiments were performed according to the relevant regulatory
standards.
Mdm2 Binding Assays
Binding to immobilized GST proteins was performed as described before
(Wei et al., 2004). Where indicated, the GST-Mdm2 proteins were incubated
with CKI in the presence of ATP for 1 hr before the binding assays.
In Vitro Kinase Assay
CKI was purchased from New England BioLabs. The CKI in vitro kinase assays
were performed according to the manufacturer’s instructions (New England
Biolab). Briefly, 5 mg of indicated GST fusion proteins were incubated with
purified active CKI in the presence of 5 mCi [g-32P] ATP and 200 mM cold
ATP in the CKI reaction buffer for 15–30 min. The reaction was stopped by
the addition of SDS-containing lysis buffer, resolved on SDS-PAGE, and
detected by autoradiography.
In Vitro Ubiquitination Assay
The in vitro ubiquitination assays were performed as described previously
(Jin et al., 2005). To purify SCF/b-TRCP1 complex, 293T cells were transfected
with vectors encoding GST- b-TRCP1, Myc-Cul-1, Myc-Skp1, and HA-Rbx1.
The SCF/b-TRCP1 (E3) complexes were purified from the whole-cell lysates
using GST-agarose beads. Before the in vitro ubiquitination assay, indicated
GST-Mdm2 proteins were incubated with purified, recombinant active CKId
in the presence of ATP (with kinase reaction buffer as a negative control) in
30C for 30 min. Afterwards, the kinase reaction products were incubatedwith purified SCF/b-TRCP1 (E3) complexes in the presence of purified,
recombinant active E1, E2 (UbcH5a and UbcH3), ATP, and ubiquitin. The reac-
tions were stopped by the addition of 23 SDS-PAGE sample buffer and the
reaction products were resolved by SDS-PAGE gel and probed with the indi-
cated antibodies.
Additional experimental procedures are included in Supplemental Experi-
mental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental References, seven figures and can be found with this article
online at doi:10.1016/j.ccr.2010.06.015.
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